PD33-06 DIFFERENCES IN ADVANCED THERAPEUTIC MODALITIES FOR OVERACTIVE BLADDER OR URGENCY URINARY INCONTINENCE IN THE US BY RACE

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD33-06 DIFFERENCES IN ADVANCED THERAPEUTIC MODALITIES FOR OVERACTIVE BLADDER OR URGENCY URINARY INCONTINENCE IN THE US BY RACE Pranjal Agrawal, Chi Chiung Grace Chen, and Marisa Clifton Pranjal AgrawalPranjal Agrawal More articles by this author , Chi Chiung Grace ChenChi Chiung Grace Chen More articles by this author , and Marisa CliftonMarisa Clifton More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003326.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Reducing healthcare disparities includes advancing equity for our patients. Significant disparities exist in the diagnosis & treatment of overactive bladder (OAB). Our objective was thus to analyze if race influences receipt of advance therapies for urgency urinary incontinence (UUI) or OAB. METHODS: The TriNetX Diamond network was queried to identify adult females with a diagnosis of UUI (N39.41) or OAB (N32.81), excluding those with stress incontinence (N39.3) or mixed incontinence (N39.46). Propensity-score matching was conducted for age at diagnosis, current age, outpatient (1013626), inpatient (1013659), & emergency department (1013711) service utilizations. Treatments were categorized according to AUA guidelines: 1st line therapies included biofeedback training (90911, 90912, 90913, 1035670) or physical therapy (97161, 97162, 97163, Z51.89, 1029677); 2nd line included oxybutynin (32675), darifenacin (136198), solifenacin (322167), tolterodine (119565), fesoterodine (797195), trospium chloride (236778), or mirabegron (1300786); 3rd line included percutaneous tibial nerve stimulation (64581), sacral neuromodulation (64561, 64566), or OnabotulinumtoxinA injection (52287, J0585) in 1, 3, or 5 years from diagnosis. RESULTS: We identified 1,534,042 adult females with OAB or UUI; 437,401 identified as white & 57,458 identified as black. The number of individuals receiving treatment & advancement in treatment over the years are listed in Table 1. 57,413 black females were compared to an equivalent number of propensity-score matched white females. No significant difference was observed in initial access to 1st line treatment. Significant difference was observed in advanced treatment prescriptions between race (Table 2). CONCLUSIONS: Though initial 1st line treatment prescription is similar by race; our results demonstrate a significantly lower rate of prescription of 2nd or 3rd line therapies for black individuals. These results highlight the need for further research to understand these differences. Source of Funding: NA © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e915 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Pranjal Agrawal More articles by this author Chi Chiung Grace Chen More articles by this author Marisa Clifton More articles by this author Expand All Advertisement PDF downloadLoading ...